Parker Bioscience Filtration Expands Single-Use System Facility in UK

News
Article

The Birtley, UK facility added cleanroom, manufacturing, and testing facilities for biopharma manufacturing single-use systems.

Parker Bioscience Filtration, which supplies automated single-use solutions that include filtration, single-use fluid-handling systems, and sensors, opened expanded facilities at its Birtley, United Kingdom site, including new cleanroom, manufacturing, and testing facilities, the company announced in a Aug. 15, 2019 press release. The SciLog Suite supports process development by providing a facility to test and optimize unit operations within a production process. The facility includes the SciLog FD for bulk drug filtration and dispense, the SciLog TFF for tangential flow filtration operations, and the SciLog NFF for normal flow filtration operations. The facility can accommodate more than 20 people. 

Earlier this year, as part of the same investment program, the company announced the opening of a new cleanroom facility at the site that is dedicated to the manufacture of single-use assemblies. 

“It’s hugely exciting to have opened the doors to our extended and refurbished site in Birtley. The investment in these facilities demonstrates Parker Hannifin’s commitment to our European customer base and through this, we have strengthened the level of technical support and service that we can offer across biopharmaceutical manufacturing.We have shortened the supply chain for our European customers and made it easier for customers to access filtration solutions and automated systems,” said Kris Holmes, general manager of Parker Bioscience Filtration, in the press release. “In addition, we have also provided a greatly enhanced working environment for Parker Bioscience Filtration’s specialist workforce. The overall investment in our laboratory, cleanroom, manufacturing, office, and warehouse facilities has made our Birtley premises one of the most modern manufacturing sites for integrated bioprocessing solutions in EMEA.”

Source: Parker

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Related Content